ARTICLE | Company News
Aegerion cuts jobs as Juxtapid competition grows
February 12, 2016 2:27 AM UTC
Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) said it will cut costs and reduce global staff by 25% as its hypercholesterolemia treatment Juxtapid lomitapide faces increased competition.
The company said in January it expected Juxtapid sales to be $37.5-$39.5 million in 4Q15 and $211-$213 million for the year. In November, Aegerion said switches to PCSK9 inhibitors were higher than expected (see BioCentury Extra, Nov. 10, 2015). ...